Vafi Salmasi, MD
Anesthesiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Salmasi’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A141155 · Current
Licensed to practise in California · since 2016 · expires 2027-09-30 · Tehran University of Medical Sciences and Health Services.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$29,871
Medicare paid this office $29,871 for 158 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 30 | $5,836 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $2,902 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,150 | $86 |
| Return visit (30+ min) | 16 | $1,939 | $114 |
| New patient visit (60+ min) | 11 | $1,816 | $165 |
See all 11 services
| Long return visit (40+ min) | 30 | $5,836 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $2,902 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,150 | $86 |
| Return visit (30+ min) | 16 | $1,939 | $114 |
| New patient visit (60+ min) | 11 | $1,816 | $165 |
| Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | 21 | $1,532 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,379 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,339 | $70 |
| Administration of psychological or neuropsychological test, first 30 minutes | 29 | $1,086 | $27 |
| Each additional 15 minutes of chronic pain management and treatment by a physician or other qualified health care professional, per calendar month. (list separately in addition to code for g3002. when using g3003, 15 minutes must be met or exceeded.) | 11 | $251 | $23 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | $178 | $10 |
Who their Medicare patients are
158 Original Medicare patients in 2024. Average age 71 · Under 65 19% · 85 and older 10% · Women 65% · Also on Medicaid 28% · Health risk score 1.65. Above the middle of the specialty; the typical anesthesiology clinician is at 1.54.
Conditions among them: High blood pressure 73% · Depression 34% · Diabetes 29% · Chronic kidney disease 27% · Coronary heart disease 22% · COPD 16% · Atrial fibrillation 16% · Cancer 15% · Heart failure 14% · Stroke 8% · Dementia 7%.
The office billed $455,462, Medicare allowed $40,809 and paid $29,871; for 353 services of 43 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 158 | 353 | 71 | 1.65 | $455,462 | $29,871 |
| 2023 | 315 | 694 | 69 | 1.94 | $588,035 | $64,467 |
| 2022 | 422 | 957 | 69 | 1.69 | $923,319 | $86,817 |
| 2021 | 452 | 1,064 | 69 | 1.75 | $896,628 | $87,859 |
| 2020 | 236 | 505 | 68 | 1.77 | $486,278 | $40,313 |
| 2019 | 415 | 834 | 69 | 1.62 | $444,197 | $65,345 |
| 2018 | 272 | 506 | 68 | 1.52 | $296,452 | $32,842 |
| 2017 | 68 | 105 | 67 | 1.32 | $41,692 | $7,558 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 112 | $14,024 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $11,601 | $73 |
| Long return visit (40+ min) | 41 | $7,661 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $5,924 | $110 |
| Return visit (30+ min) | 28 | $2,610 | $84 |
| Daily hospital management of continuous spinal drug administration | 24 | $1,979 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,975 | $152 |
| Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | 13 | $1,006 | $67 |
| Administration of psychological or neuropsychological test, first 30 minutes | 13 | $355 | $21 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 29 | $136 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 14 | $66 | $5 |
2022: 11 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 126 | $15,987 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 152 | $15,025 | $65 |
| Long return visit (40+ min) | 62 | $11,394 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $3,633 | $93 |
| Daily hospital management of continuous spinal drug administration | 36 | $3,560 | $56 |
| New patient visit (60+ min) | 21 | $3,169 | $151 |
| Return visit (30+ min) | 29 | $3,142 | $81 |
| Injection of trigger points, 3 or more muscles | 16 | $482 | $28 |
| Ultrasonic guidance for needle placement | 11 | $371 | $27 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 44 | $213 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 17 | $101 | $5 |
2021: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 162 | $16,929 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 120 | $15,567 | $126 |
| Long return visit (40+ min) | 42 | $9,734 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $5,632 | $95 |
| Daily hospital management of continuous spinal drug administration | 35 | $3,868 | $57 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 15 | $3,222 | $201 |
| New patient visit (60+ min) | 22 | $3,118 | $142 |
| Return visit (30+ min) | 28 | $2,993 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,776 | $185 |
| Ultrasonic guidance for needle placement | 37 | $1,372 | $27 |
| Injection of substance into lower spine canal using imaging guidance | 14 | $1,290 | $92 |
| Injection of trigger points, 3 or more muscles | 26 | $1,180 | $37 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 14 | $987 | $58 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $557 | $29 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 40 | $418 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $206 | $11 |
2020: 8 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 58 | $8,152 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $6,236 | $68 |
| Return visit (30+ min) | 40 | $3,987 | $66 |
| New patient visit (60+ min) | 15 | $2,161 | $144 |
| Daily hospital management of continuous spinal drug administration | 15 | $1,564 | $58 |
| Short return visit (20+ min) | 13 | $716 | $45 |
| Ultrasonic guidance for needle placement | 23 | $644 | $28 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 36 | $403 | $10 |
2019: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 143 | $14,506 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 107 | $14,024 | $122 |
| Return visit (30+ min) | 58 | $5,316 | $64 |
| New patient visit (60+ min) | 32 | $4,511 | $141 |
| Daily hospital management of continuous spinal drug administration | 28 | $3,689 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,075 | $181 |
| Long return visit (40+ min) | 19 | $1,575 | $83 |
| Ultrasonic guidance for needle placement | 40 | $1,115 | $27 |
| Short return visit (20+ min) | 15 | $894 | $45 |
| Injection of trigger points, 3 or more muscles | 20 | $801 | $35 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 11 | $510 | $39 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $343 | $12 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $131 | $11 |
2018: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $5,230 | $65 |
| New patient visit (60+ min) | 34 | $4,392 | $129 |
| Return visit (30+ min) | 54 | $3,829 | $58 |
| Long return visit (40+ min) | 21 | $1,915 | $91 |
| Ultrasonic guidance for needle placement | 52 | $1,533 | $29 |
| Injection of trigger points, 3 or more muscles | 27 | $1,132 | $38 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 20 | $977 | $47 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 42 | $526 | $11 |
2017: 2 services
| New patient visit (60+ min) | 14 | $2,094 | $150 |
| Return visit (30+ min) | 21 | $1,824 | $70 |
Medicaid work
$743 in 2024
Medicaid paid $743 for 27 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 27 | $743 |
| 2024 | 27 | 1 | 12 | $743 |
| 2023 | 84 | 1 | 16 | $3,003 |
| 2022 | 33 | 2 | 15 | $1,393 |
| 2021 | 128 | 1 | 15 | $3,646 |
| 2020 | 17 | 1 | 16 | $860 |
| 2019 | 46 | 1 | 17 | $789 |
| 2018 | 25 | 2 | 12 | $723 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 84 | $3,003 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 21 | $916 |
| Long return visit (40+ min) | 12 | $477 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 128 | $3,646 |
2020
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 17 | $860 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 46 | $789 |
2018
| Injection(s); single tendon sheath, or ligament, aponeurosis (eg, plantar "fascia") | 13 | $431 |
| Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation | 12 | $292 |
Drugs they prescribed that Part D paid
$19,134
Pharmacies billed $19,134 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 22% of their Part D prescriptions (60 of 269) in 2024. Above the middle of the specialty; the typical anesthesiology clinician is at 0%. Long-acting opioids: 52% of their opioid prescriptions.
264 generic and fewer than 11 brand-name prescriptions · $19,134 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Buprenorphine | 23 | $8,245 | $358 |
| Gabapentin | 17 | $838 | $49 |
| Baclofen | 21 | $356 | $17 |
| Duloxetine | 21 | $299 | $14 |
| Topiramate | 20 | $177 | $9 |
See all 10 drugs
| Buprenorphine | 23 | $8,245 | $358 |
| Gabapentin | 17 | $838 | $49 |
| Baclofen | 21 | $356 | $17 |
| Duloxetine | 21 | $299 | $14 |
| Topiramate | 20 | $177 | $9 |
| Acetaminophen-Codeine | 11 | $175 | $16 |
| Celecoxib | 20 | $163 | $8 |
| Cyclobenzaprine | 17 | $151 | $9 |
| Pregabalin | 15 | $151 | $10 |
| Meloxicam | 12 | $74 | $6 |
Year by year
| 2024 | 269 | 42 | 22% (60) | None | $19,134 |
| 2023 | 322 | 44 | 27% (88) | 7% | $27,018 |
| 2022 | 379 | 76 | 29% (110) | 8% | $27,047 |
| 2021 | 381 | 72 | 24% (92) | 4% | $19,833 |
| 2020 | 360 | 65 | 14% (50) | 4% | $16,215 |
| 2019 | 343 | 63 | 15% (50) | 7% | $22,422 |
| 2018 | 363 | 78 | 17% (63) | 12% | $31,121 |
| 2017 | 69 | 32 | None | None | $4,897 |
| 2016 | 28 | 13 | None | 39% | $6,090 |
| 2015 | 75 | 26 | None | 24% | $9,174 |
| 2013 | 23 | None | None | None | $232 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Emgality | Migraine | 11 | $8,307 | $755 |
| Buprenorphine | None | 17 | $6,300 | $371 |
| Baclofen | None | 37 | $1,413 | $38 |
| Gabapentin | None | 17 | $1,228 | $72 |
| Celecoxib | None | 28 | $1,141 | $41 |
| Pregabalin | None | 12 | $530 | $44 |
| Duloxetine | None | 23 | $503 | $22 |
| Hydrocodone-Acetaminophen | None | 13 | $326 | $25 |
| Meloxicam | None | 13 | $95 | $7 |
| Cyclobenzaprine | None | 16 | $64 | $4 |
2022: 11 drugs
| Buprenorphine | 22 | $5,924 | $269 |
| Oxycodone | 29 | $3,186 | $110 |
| Duloxetine | 30 | $1,226 | $41 |
| Pregabalin | 30 | $997 | $33 |
| Oxycodone-Acetaminophen | 15 | $620 | $41 |
| Gabapentin | 23 | $563 | $24 |
| Hydrocodone-Acetaminophen | 14 | $405 | $29 |
| Baclofen | 23 | $397 | $17 |
| Mirtazapine | 11 | $369 | $34 |
| Celecoxib | 18 | $175 | $10 |
| Cephalexin | 13 | $66 | $5 |
2021: 14 drugs
| Buprenorphine | 17 | $4,844 | $285 |
| Clonidine | 25 | $2,240 | $90 |
| Duloxetine | 36 | $2,041 | $57 |
| Etodolac Er | 11 | $891 | $81 |
| Cyclobenzaprine | 32 | $881 | $28 |
| Baclofen | 21 | $821 | $39 |
| Oxycodone-Acetaminophen | 11 | $790 | $72 |
| Celecoxib | 14 | $688 | $49 |
| Gabapentin | 29 | $600 | $21 |
| Pregabalin | 17 | $525 | $31 |
| Oxycodone | 16 | $490 | $31 |
| Hydrocodone-Acetaminophen | 14 | $469 | $34 |
| Topiramate | 17 | $196 | $12 |
| Meloxicam | 12 | $46 | $4 |
2020: 11 drugs
| Buprenorphine | 12 | $3,626 | $302 |
| Buprenorphine | 18 | $1,884 | $105 |
| Pregabalin | 24 | $1,359 | $57 |
| Clonidine | 14 | $1,104 | $79 |
| Duloxetine | 23 | $950 | $41 |
| Gabapentin | 53 | $852 | $16 |
| Topiramate | 19 | $655 | $34 |
| Baclofen | 19 | $481 | $25 |
| Oxycodone | 13 | $206 | $16 |
| Cyclobenzaprine | 12 | $188 | $16 |
| Meloxicam | 20 | $80 | $4 |
2019: 10 drugs
| Clonidine | 18 | $1,613 | $90 |
| Gabapentin | 42 | $1,305 | $31 |
| Baclofen | 28 | $690 | $25 |
| Oxcarbazepine | 12 | $478 | $40 |
| Duloxetine | 15 | $296 | $20 |
| Nortriptyline | 19 | $264 | $14 |
| Topiramate | 15 | $203 | $14 |
| Meloxicam | 20 | $82 | $4 |
| Acetaminophen-Codeine | 14 | $52 | $4 |
| Cyclobenzaprine | 13 | $51 | $4 |
2018: 11 drugs
| Lyrica | 12 | $7,549 | $629 |
| Mexiletine | 13 | $2,486 | $191 |
| Clonidine | 20 | $1,801 | $90 |
| Gabapentin | 40 | $1,208 | $30 |
| Duloxetine | 26 | $967 | $37 |
| Baclofen | 25 | $496 | $20 |
| Meloxicam | 14 | $296 | $21 |
| Memantine | 22 | $243 | $11 |
| Topiramate | 24 | $221 | $9 |
| Nortriptyline | 17 | $210 | $12 |
| Hydrocodone-Acetaminophen | 11 | $146 | $13 |
2015: 1 drug
| Gabapentin | 15 | $238 | $16 |
Money from drug and device companies
$30,269 in 2025
| 2025 | 8 | 39 | $26,438 | $30,269 |
| 2024 | 9 | 42 | $6,706 | $10,641 |
| 2023 | 8 | 23 | $2,200 | $6,567 |
| 2022 | 4 | 6 | None | $325 |
| 2021 | 4 | 18 | $750 | $1,120 |
| 2020 | 4 | 13 | $3,300 | $5,293 |
| 2019 | 2 | 5 | None | $800 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Stryker | Mild Device Kit | $15,001 | 14 payments
|
| Vertex Pharmaceuticals | Journavx | $10,397 | 9 payments
|
| SPR Therapeutics | Sprint Pns System | $3,422 | 4 payments
|
| Biotronik Nro | Prospera | $996 | 6 payments
|
| Medtronic | Inceptiv | $140 | 3 payments
|
| Boston Scientific | General - Pain Management | $130 | 1 payment
|
See all 39 published payments
| Stryker | Consulting · 2025-12-29 | Spinejack | $250 |
| Stryker | Consulting · 2025-12-29 | Mild Device Kit | $7,500 |
| SPR Therapeutics | Consulting · 2025-12-18 | Sprint Pns System | $500 |
| Stryker | Consulting · 2025-12-12 | Mild Device Kit | $1,000 |
| Medtronic | Meals · 2025-12-08 | Inceptiv | $7 |
| Stryker | Meals · 2025-12-06 | Optablate | $23 |
| Stryker | Meals · 2025-12-06 | Optablate | $29 |
| Stryker | Consulting · 2025-12-04 | Mild Device Kit | $250 |
| SPR Therapeutics | Consulting · 2025-11-20 | Sprint Pns System | $2,750 |
| Stryker | Travel · 2025-10-09 | Optablate | $12 |
| Stryker | Travel · 2025-10-08 | Mild Device Kit | $189 |
| Biotronik Nro | Meals · 2025-10-08 | Prospera | $230 |
| Stryker | Travel · 2025-10-02 | Optablate | $312 |
| Stryker | Travel · 2025-09-30 | Optablate | $35 |
| Stryker | Meals · 2025-09-27 | Optablate | $24 |
| Stryker | Meals · 2025-09-27 | Optablate | $28 |
| Medtronic | Meals · 2025-09-20 | Inceptiv | $18 |
| SPR Therapeutics | Meals · 2025-09-19 | Sprint Pns System | $88 |
| Medtronic | Meals · 2025-09-19 | Inceptiv | $115 |
| Abbott Laboratories | Meals · 2025-09-19 | Proclaim | $114 |
| Biotronik Nro | Meals · 2025-09-18 | Prospera | $149 |
| Biotronik Nro | Meals · 2025-09-16 | Prospera | $172 |
| Biotronik Nro | Meals · 2025-09-11 | Prospera | $86 |
| Vertex Pharmaceuticals | Paid to speak or teach · 2025-08-14 | Journavx | $1,838 |
| Stryker | Travel · 2025-08-08 | Mild Device Kit | $349 |
| Biotronik Nro | Meals · 2025-07-18 | Prospera | $142 |
| Vertex Pharmaceuticals | Meals · 2025-07-10 | Journavx | $122 |
| Stryker | Consulting · 2025-06-27 | None | $5,000 |
| Vertex Pharmaceuticals | Paid to speak or teach · 2025-06-05 | Journavx | $788 |
| Vertex Pharmaceuticals | Paid to speak or teach · 2025-04-24 | Journavx | $3,675 |
| Vertex Pharmaceuticals | Paid to speak or teach · 2025-04-24 | Journavx | $2,888 |
| Boston Scientific | Meals · 2025-03-30 | General - Pain Management | $130 |
| SPR Therapeutics | Meals · 2025-03-29 | Sprint Pns System | $83 |
| Saluda Medical Americas | Meals · 2025-03-25 | Evoke | $71 |
| Vertex Pharmaceuticals | Travel · 2025-03-22 | Journavx | $340 |
| Vertex Pharmaceuticals | Travel · 2025-03-22 | Journavx | $632 |
| Vertex Pharmaceuticals | Meals · 2025-03-22 | Journavx | $66 |
| Vertex Pharmaceuticals | Meals · 2025-03-22 | Journavx | $50 |
| Biotronik Nro | Meals · 2025-02-26 | Prospera | $218 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $10,641
| SPR Therapeutics | Sprint Pns System | $3,327 | 5 payments
|
| Vertos Medical | Mild Device Kit | $2,799 | 4 payments
|
| Bioventus | Stimrouter Implantable Kit | $1,831 | 4 payments
|
| Medtronic | Kyphon Express II Kyphopak Tray | $751 | 12 payments
|
| Boston Scientific | None | $598 | 4 payments
|
| Painteq | Painteq | $556 | 7 payments
|
| Saluda Medical Americas | Evoke | $464 | 4 payments
|
| Abbott Laboratories | Eterna | $171 | 1 payment
|
| Biotronik Nro | Prospera | $145 | 1 payment
|
2023: $6,567
| SPR Therapeutics | Sprint Pns System | $3,314 | 4 payments
|
| Saluda Medical Americas | Evoke Scs | $1,647 | 7 payments
|
| Nevro | Senza | $327 | 3 payments
|
| Biotronik Nro | Biotronik | $310 | 2 payments
|
| Vertos Medical | Mild Device Kit | $307 | 2 payments
|
| Painteq | Painteq | $297 | 2 payments
|
| Boston Scientific | None | $194 | 2 payments
|
| Medtronic | None | $171 | 1 payment
|
2022: $325
| Boston Scientific | General - Pain Management | $98 | 1 payment
|
| SPR Therapeutics | Sprint Pns System | $86 | 1 payment
|
| Abbott Laboratories | Proclaim | $72 | 3 payments
|
| Bioventus | Stimrouter Implantable Kit | $68 | 1 payment
|
2021: $1,120
| Vertos Medical | Mild Device Kit | $750 | 1 payment
|
| Abbott Laboratories | Proclaim Ipg | $264 | 14 payments
|
| Stimwave Technologies | Stimq Receiver Stimulator Kit Channel A US W Receiver | $62 | 1 payment
|
| Relievant Medsystems | Intracept | $44 | 2 payments
|
2020: $5,293
| Biotronik | None | $3,980 | 6 payments
|
| Vertos Medical | Mild Device Kit | $1,210 | 5 payments
|
| Si-Bone | Ifuse Implant | $87 | 1 payment
|
| Abbott Laboratories | Prodigy Family of Scs Ipgs | $16 | 1 payment
|
2019: $800
| Bioness | Stimrouter for Pain | $531 | 1 payment
|
| Nevro | Senza Spinal Cord Stimulation System | $269 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1649542382
- Licence
- CA A141155California A141155: Current · expires 2027-09-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LP2900X (207LP2900X); Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-01-26
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.